Search

High-energy carbon-ion radiotherapy is being carried out at Heavy Ion Medical Accelerator in Chiba (HIMAC). Over 12000 cancer patients have been treated with carbon beams having energies of between 56-430 MeV/u since 1994. There are two injectors in the HIMAC for medical and experimental use. First injector consists of two ECR ion sources and one PIG ion source, the RFQ linac and the DTL. Usually, this injector suppling the carbon ion for cancer therapy and various ion such as H, He, Fe, Xe are accelerated for biological and physical experiment. The 10 GHz NIRS-ECR ion source produce the carbon ion for cancer therapy. The 18 GHz NIRS-HEC ion source produce He to Xe ions for experimental use. Second injector consists of the compact ECR ion source with all permanent magnet, the RFQ linac and the APF IH-DTL. This injector supplies the carbon ion for experimental use. Additionally, we tried production of the Indium and the Tin ions by using the In(C5H5) and the Sn(i-C3H7)4 at the NIRS-HEC. Beam current of the 115In20+ and 120Sn18+ were 90 and 15 microA, respectively., 24th International Workshop on ECR Ion Sources

Aska Toda,1 Kenjiro Sawada,1 Keigo Osuga,2 Noboru Maeda,2 Hiroki Higashihara,2 Tomoyuki Sasano,1 Noriyuki Tomiyama,2 Tadashi Kimura1 1Department of Obstetrics and Gynecology, 2Department of Diagnostic and Interventional Radiology, Osaka University Graduate School of Medicine, Osaka, Japan Aim: The aim of this study was to retrospectively analyze the efficacies of uterine artery embolization (UAE) using gelatin sponge for symptomatic uterine fibroids.Methods: A series of 60 consecutive premenopausal women underwent UAE using gelatin sponge particles or porous gelatin particles. Patients were routinely followed up at 1, 3, 6, and 12months after the procedure and asked to report any procedure-related complications. At each follow-up, an original clinical questionnaire was completed by the patients to evaluate changes in fibroid-related symptoms. Pelvic magnetic resonance imaging was performed before and at 3 and 12months after the procedure, and the changes in volume of the dominant fibroid were calculated.Results: Bilateral UAE was successfully performed in all the patients. Median age was 45years (range 34–53years), and median follow-up period was 25.2months (range 1–116months). At the 3- and 12-month follow-up, the dominant fibroid volumes were found to be significantly decreased by 33.4% (95% confidence interval [CI]: 24.9–41.1) and 48.4% (95% CI: 40.7–56.1) compared to baseline volumes, respectively. Excluding patients not having menorrhagia or bulk-related symptoms, at 12 months 49 of 50 (98%) women showed improvement in menorrhagia, and 45 of 47 (95.7%) women showed improvement in bulk-related symptoms. During the follow-up period, ten patients (16.7%) required further interventions including two patients who had undergone hysterectomy. No sequelae were experienced by any of the patients.Conclusion: UAE using gelatin sponge was associated with a high clinical success rate and good fibroid volume reduction compared to UAE using other embolic agents. Keywords: embolic agent, gelatin sponge, uterine artery embolization, uterine fibroid

Mihoko Kawabata,1 Yasuhiro Yokoyama,1 Takeshi Sasaki,1 Susumu Tao,1 Kensuke Ihara,1 Yasuhiro Shirai,1 Tetsuo Sasano,2 Masahiko Goya,1 Tetsushi Furukawa,3 Mitsuaki Isobe,4 Kenzo Hirao1 1Heart Rhythm Center, Tokyo Medical and Dental University, Tokyo, Japan; 2Department of Biofunctional Informatics, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan; 3Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan; 4Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan Purpose: Drug-induced bradycardia is common during antiarrhythmic therapy; the major culprits are beta-blockers. However, whether other antiarrhythmic drugs are also a significant cause of this, alone or in combination with beta-blockers, is not well known. Methods: We retrospectively investigated the records of all patients hospitalized at our institution for drug-related bradycardia from the years 2004 to 2012. Patients with cardiac disease and electrolytic or hormonal abnormalities that could cause bradyarrhythmias were excluded. Results: Eight patients were identified (mean age, 79±5 years; range, 71–85 years; 6 women). Three patients were taking only beta-blockers (hereafter referred to as the BB group), while five patients were on both beta-blockers and Na channel blockers (hereafter referred to as the BB + Na group). Heart rates ranged from 20~49 beats/minute on arrival. The initial electrocardiogram showed sinus bradycardia (n=6) or sinus arrest with escape beats (n=2). QRS duration was 80–100 ms. The clinical presentation of the BB + Na group was considerably worse than that of the BB group, and included cardiogenic shock and heart failure. Four of the BB + Na patients had been on their medications for over 300 days. The BB group recovered solely with drug discontinuation, while 4 of the 5 patients in the BB + Na group needed additional treatments, such as intravenous administration of atropine or adrenergic agonist and temporary pacing. Bradycardia did not recur during follow-up (median, 687 days). Conclusion: Although wide QRS ventricular tachyarrhythmia is a better known proarrhythmic effect of Na channel blockers, life-threatening bradycardia may also occur in combination with beta-blockers in the elderly, even months after the start of medication, and at plasma concentrations that do not prolong QRS width. Keywords: proarrhythmia, elderly, QRS duration

The Heavy Ion Medical Accelerator in Chiba (HIMAC) was constructed as the first medical dedicated heavy ion accelerator facility at National Institute of Radiological Sciences (NIRS). Over 9000 cancer patients have been treated with 140-430 MeV/u carbon beams since 1994. Compact ECR ion source with all permanent magnets, named Kei2, was developed for production of C4+ ions for medical treatment at NIRS. A compact ECR ion source for Gunma University (Gunma University Heavy Ion Medical Center: GHMC), Saga carbon-ion radiotherapy (Saga Heavy Ion Medical Accelerator in Tosu: SAGA HIMAT) and Kanagawa carbon-ion radiotherapy (Ion-beam Radiation Oncology Center in Kanagawa: i-ROCK) facility has been operated for medical use. It is a copy of the Kei2 which was developed by NIRS. In order to reduce operation cost of the injector for next designed carbon ion facility, we start design of new compact ECR ion source for C5+ production. Some dependence (mirror field, microwave power and frequency) were checked for optimal parameter of C5+ production at 18 GHz NIRS-HEC source. Results of experiments and specification of new compact source are described in this presentation., The 22nd International Workshop on ECR Ion Sources (ECRIS2016)